JNJ-54861911, 25 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Alzheimer DiseaseHealthy

Phase 1

A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants

CompletedNCT02197884

Janssen Research & Development, LLCHealthy

Start: 2014-07-31End: 2014-09-30Updated: 2014-10-15

Phase 2

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

TerminatedNCT02406027

Janssen Research & Development, LLCAlzheimer Disease

Start: 2015-07-02End: 2018-06-28Updated: 2025-04-29

Related Papers

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.

2020-05-1480 citations